Blood Eosinophil Count Stability in COPD and the Eosinophilic Exacerbator Phenotype

Affiliations

¹ Respiratory Medicine, University of Ferrara, Italy, Ferrara, Italy.
² Imperial College London National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
³ Imperial College London, National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
⁴ Imperial College London National Heart and Lung Institute, Airways disease, London, United Kingdom of Great Britain and Northern Ireland.
⁵ University of Ferrara, Research Centre on Asthma and COPD, Ferrara, Italy.
⁶ Imperial College London National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland; l.finney@imperial.ac.uk.

Federico Baraldi et al. Am J Respir Crit Care Med. 2025.

. 2025 Jan 15;211(5):870-872.

doi: 10.1164/rccm.202407-1287RL. Online ahead of print.

¹ Respiratory Medicine, University of Ferrara, Italy, Ferrara, Italy.
² Imperial College London National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
³ Imperial College London, National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland.
⁴ Imperial College London National Heart and Lung Institute, Airways disease, London, United Kingdom of Great Britain and Northern Ireland.
⁵ University of Ferrara, Research Centre on Asthma and COPD, Ferrara, Italy.
⁶ Imperial College London National Heart and Lung Institute, London, United Kingdom of Great Britain and Northern Ireland; l.finney@imperial.ac.uk.

No abstract available

Keywords: COPD; Eosinophils; Exacerbations; Type II inflammation.

References

1. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med . 2018;6:117–126. - PubMed
1. Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for Chronic Obstructive Lung Disease; 2024. https://goldcopd.org/2024-gold-report/
1. Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, et al. High eosinophil counts predict decline in FEV1: results from the CanCOLD study. Eur Respir J . 2021;57:2000838. - PubMed
1. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. BOREAS Investigators Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med . 2023;389:205–214. - PubMed
1. Van Rossem I, Hanon S, Verbanck S, Vanderhelst E. Blood eosinophil counts in chronic obstructive pulmonary disease: adding within-day variability to the equation. Am J Respir Crit Care Med . 2022;205:727–729. - PubMed